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Background: Randomized placebo-controlled trials represent the gold standard in evaluating healthcare interventions
but are rarely performed within orthopedics. Ethical concerns or well-known challenges in recruiting patients for
surgical trials in general have been expressed and adding a placebo component only adds to this complexity.
The purpose of this study was to report the challenges of recruiting patients into an orthopedic placebo-controlled
surgical trial, to determine the number of patients needed to be screened and allocated in order to include one
participant into the trial, and to identify reasons associated with participation in a placebo-controlled randomized
surgical trial.
Methods: Data were extracted from an ongoing placebo-controlled randomized controlled trial (RCT) on meniscectomy
versus placebo surgery. We calculated the number of patients needed to be screened in order to include the required
number of participants into the RCT. Participating patients were asked about their rationale for joining the study and
which type of information was most useful for deciding upon participation.
Results: A total of 476 patients entered the screening group, of which 190 patients fulfilled the inclusion and
exclusion criteria. 102 patients declined to participate in the study due to various reasons and 46 were later
excluded (no meniscus lesion on the magnetic resonance imaging scan or withdrawn consent). A total of 40
patients were finally included in the RCT. To include one patient into the RCT, 11.9 individuals needed to be screened.
A total of 69% of participating patients considered the oral information to be the most important and the most
common reason for participating was the contribution to research (90%).
Conclusions: Patients are willing to participate in an orthopedic placebo-controlled surgical trial. Oral information
given by the surgeon to the patient and the contribution to research are important aspects to enhance patient
recruitment.
Trial registration: ClinicalTrials.gov NCT01264991, registered 21 December 2010.
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Randomized controlled trials (RCTs) represent the gold
standard in evaluating healthcare interventions. The
randomization of treatment and blinding of group alloca-
tion to the investigator and participants, possibly by use of
a placebo, reduces bias [1]. Though this design is consid-
ered gold standard in therapeutic trials this has not been
the case within the field of surgery. Ethical concerns [2,3]* Correspondence: kbhr@regionsjaelland.dk
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unless otherwise stated.or well-known challenges in recruiting patients for surgi-
cal trial in general [4,5] have been expressed and adding a
placebo component only adds to this complexity.
We are not aware of any studies on the challenge of
recruiting patients for a placebo-controlled orthopedic
trial, specific screening procedures for identifying eligible
patients, or motivation of patients to participate in a
placebo-controlled orthopedic trial. One study on feasibil-
ity and acceptance showed that an orthopedic placebo-
controlled trial could be conducted in principle, albeit
with difficulty [6]. The challenge of recruitment for an
orthopedic RCT comparing rehabilitation plus early sur-
gery with rehabilitation plus optional later surgery for and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Inclusion and exclusion criteria in the RCT of APM
versus placebo surgery of degenerative meniscus tears
Inclusion criteria
1. Knee pain > 2 months without significant trauma
2. MRI confirmed medial meniscus lesion
3. Age 35-55
4. Eligible for outpatient surgery
Exclusion criteria
1. Need for acute surgery, i.e. locking knees, high energy trauma
2. Symptoms from other musculoskeletal disorder overriding
symptoms of the knee
3. Grade 3 or 4 knee OA on the Kellgren-
4. Lawrence classification
5. Knee surgery within the last 2 years
6. BMI > 35
7. Ischemic heart disease
8. Diabetic late complications
9. Thrombophilia
10. Pregnancy
11. Unable to speak Danish
12 Drug or alcohol abuse
APM, arthroscopic partial meniscectomy; BMI, Body Mass Index; OA,
osteoarthritis; RCT, randomized controlled trial.
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ported, [7] but similar reports from placebo-controlled tri-
als are lacking. Earlier placebo-controlled orthopedic
studies have reported a recruitment rate between 35 and
71% [8-10] but no information exists on patient’s prefer-
ences and determinants of willingness to participate in an
orthopedic placebo-controlled study.
Arthroscopic partial meniscectomy (APM) is the most
commonly performed orthopedic procedure, carried out
on 1 million patients annually in the United States [11].
The mean age in most studies is around 50 years of age
[8,12-14], indicating the vast majority of procedures being
performed in patients with a degenerative disease. Both
meniscus injury and meniscectomy are associated with
the development of knee osteoarthritis (OA) [15-17]. Pre-
vious studies in patients with or without concomitant OA
have found APM to be no better than, or have no add-
itional benefit in comparison to, placebo surgery, lavage,
optimized non-surgical treatment, or exercise [8,12-14].
This report describes the challenges of recruiting pa-
tients into an ongoing multicenter RCT [18] comparing
APM to a placebo surgery of degenerative meniscus
tears in a younger age group (between 35 and 55 years
of age) at an earlier stage of disease. We provide the
number of patients needed to be screened (NNS), and
the number of patients needed to be allocated (NNA), in
order to include the required number of participants
into the RCT. We further identify the reasons associated
with participation in a placebo-controlled randomized
surgical trial by asking why patients were willing to par-
ticipate and which type of information was most useful
for deciding upon participation.
Methods
We recruited and screened patients aged between 35
and 55 years, having a magnetic resonance imaging
(MRI) confirmed medial meniscus lesion and at least
two months of knee pain without any previous signifi-
cant trauma. Eligible patients were randomized to pla-
cebo surgery or APM after having agreed to participate
in the RCT and after providing signed informed consent
(Table 1).
Both APM and the placebo surgery were performed
under general anesthesia but only skin incisions equiva-
lent to two standard portals were performed in the pla-
cebo group.
The complete design and methodology of the study have
been published [18]. The study is approved by the Research
Ethics Committee of Region Zealand, Denmark, and is con-
sistent with the Declaration of Helsinki.
Screening strategies
Patients referred from general practitioners were screened
for eligibility by the principal investigator, an orthopedicsurgeon in residency. If eligible, oral and written informa-
tion were given about the study including a 12-minute
DVD to view at home. A few days later the patients were
contacted by telephone and provided temporary consent
by phone, and if willing to participate they were referred
for an MRI to confirm a meniscus lesion. If their MRI
confirmed a medial meniscus lesion the patient provided
written consent, was included in the study, and signed up
for surgery if still willing to participate. The strategy of
asking patients to participate before performing an MRI
was chosen since an MRI is not routinely performed be-
fore an arthroscopy in Denmark.
Patient information
Patients eligible for an MRI all received the same oral
and written information. The oral information was given
by the principal investigator in a standardized way. Pa-
tients were informed of the nature of a degenerative me-
niscus lesion, the treatment options, and hereunder
surgery. They were informed about the lack of evidence
for the effects of meniscus surgery in older age groups.
They were then informed of the lack of trials in their age
group, the need for a study, the general concept of the
placebo effect, and the design of the current study, in-
cluding information that placebo surgery would mean
that no intervention on their meniscus tear would be
performed.
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mation apart from formal information about study origin,
study investigators, information on possible adverse events
(most common infection and deep venous thrombosis)
and other treatment modalities (such as exercise).
A 12-minute DVD was given to all eligible patients
prior to the MRI to further ensure uniform dissemin-
ation of information to all patients. The video described
the background for the study, the amount of involve-
ment for participating and showed interviews of three
different orthopedic surgeons with extensive experience
within knee surgery giving their view on the condition
and arthroscopic meniscus surgery.
Statistics
The number needed to screen (NNS) and the number
needed to allocate (NNA) are concepts used and de-
scribed in previous studies [7,19,20]. The NNS was cal-
culated by dividing the number of patients screened for
eligibility with the number of patients included in the
trial. Similarly the NNA was calculated by dividing the
number of allocated patients with the number of in-
cluded patients. All patients eligible for inclusion were
regarded as allocated. The NNS and NNA provided an es-
timate of how many patients were needed to be screened
and allocated to include one patient into the trial. Multi-
plied with the a priori determined sample size, the NNS
gives an estimate of how many patients needed to bePatients screened for eligibility
n=476
Eligible for MRI
n=190 †
Agreed to participate
n=88
Included in RCT
n=40
Not eligible
n=286
Declined participation
n=102
Not included
n=48
Figure 1 Flowchart of the recruitment process in this RCT. †4 patients un
BMI, Body Mass Index; RCT, randomized controlled trial.screened and the NNA an approximation of the total
number of eligible patients necessary.
All participating patients were asked about their ra-
tionale for joining the study: wanting to contribute to re-
search, wanting an operation no matter which type, or
other, with room for elaboration. They were also asked
which kind of information had been most beneficial in
deciding whether or not to participate: the oral informa-
tion given by the orthopedic surgeon, the written infor-
mation, or the 12-minute DVD. The proportions of these
answers were calculated and reported with 95% confi-
dence intervals (95% CI).
Results
Since the start of the study, 476 patients with a suspicion
of medial meniscus injury referred from their general
practitioner entered the screening group. A total of 190
patients fulfilled the inclusion and exclusion criteria and
were thus eligible for an MRI. However, of these, 102 pa-
tients declined to participate in the study. More specific-
ally, 77 did not wish to participate after reviewing the
patient information, the reasons being: a) not wanting
placebo surgery (38%), b) the risk of undergoing a sec-
ondary operation if allocated to the placebo group
(21%), and c) not wanting surgery at all (19%). A small
number (5%) did not want to participate in any scientific
study and 17% had other reasons, mostly work-related. A
total of 25 patients declined participation before reviewingGeneral criteria
Did not fulfill inclusion criteria, n=106
Other musculoskeletal disorder, n=79
Osteoarthritis K&L grade 3 or 4, n=51
BMI > 35, n=23
Significant trauma, n=13
Other, n=14
Reason
Not wanting a placebo operation, n=29
Risk of undergoing secondary surgery, n=16
Not wanting surgery at all, n=17
Not willing to participate in trial, n=4
Other reason, n=14
25 declined before reviewing info
Excluded after MRI
No meniscus lesion on MRI, n=29
Wanting actual surgery, n=7
Not wanting surgery, n=7
Other reason, n=3
2 patients still await MRI
derwent an MRI which was negative before being informed of the study.
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participation were not collected. In addition, 46 were ex-
cluded after no visible meniscus tear was seen on MRI. Fi-
nally, 40 patients were included in the RCT (Figure 1). To
include one patient into the RCT, 11.9 individuals with a
suspected meniscus lesion needed to be screened. Simi-
larly, the NNA was 4.8 individuals eligible for inclusion
(prior to MRI) needed in order to include one patient in
the RCT.
Of the 40 included patients, the most common reason
for participating was the contribution to research (90%
(80 to 100, 95% CI)) compared to other reasons (10%
(0 to 20, 95% CI), P < 0.001). A total of 69% (54 to 84,
95% CI) of participating patients considered the oral in-
formation from the orthopedic surgeon as the most im-
portant compared to the written information and DVD
(31% (16 to 46, 95% CI), P < 0.05).
Discussion
There is a great need for randomized controlled, including
placebo-controlled, orthopedic trials. The most common
reasons for this lack of placebo-controlled surgical RCTs
include ethical issues and difficulty in recruiting pa-
tients. The recruitment of patients into orthopedic RCTs
is a well-recognized challenge [4,5] and adding a placebo
component to the trial potentially further complicates
recruitment.
In our placebo-controlled study we showed that 46%
of patients fulfilling clinical eligibility criteria were will-
ing to participate in a placebo-controlled arthroscopy
trial, fully aware they would have general anesthesia and
possibly surgery without any real intervention being per-
formed. These patients weighted the oral information
given as more important than the written information
and the 12-minute DVD when deciding whether to par-
ticipate or not. They also reported that the contribution
to science was the main reason for participating, which
is similar to other studies [21-23].
A NNS of 11.9 is high, compared to other trials of
orthopedic surgery. Buchbinder et al. [9] reported a NNS
of 6 for their placebo-controlled RCT of vertebroplasty
and Frobell et al. [7] reported an NNS of only 5.5 in their
RCT study comparing rehabilitation plus early surgery
with rehabilitation plus optional later surgery for an acute
ACL injury. One other study by Katz et al. [12] comparing
APM in combination with physiotherapy or physiotherapy
alone reported a NNS of 41.1, indicating only a minority
of patients meeting the inclusion criteria. The NNS is
markedly affected by the screening strategy, pathoanatomy
and clinical inclusion criteria, and planned interventions,
and hence will vary between different trials for different
conditions. In this study the high NNS was influenced
by the fact that the screening was made on a broad popu-
lation of patients referred from general practitioners lessexperienced in knee examination and before any imaging
was performed. Thus patients with symptoms and clinical
signs not related to an MRI-verified meniscus injury con-
stituted a large part of the screening population. Perform-
ing an MRI after clinical screening meant that more
patients had to be screened. Future clinical trials of menis-
cus surgery may consider performing an MRI earlier dur-
ing the screening process to lower the number of patients
seen by the clinician. Degenerative meniscus tears are dif-
ficult to detect and assess by clinical examination alone
[24] and in the present study an MRI failed to show a me-
niscus tear in 33% of eligible symptomatic patients willing
to participate, confirming a poor correlation between clin-
ical signs and MRI findings in this patient group [16,25].
The NNA of 4.8 was also higher than other compar-
able studies: the NNA for the vertebroplasty trial [9] was
2.1, for the ACL treatment trial [26] 1.6, and for another
placebo-controlled study of medial degenerative tears by
Sihvonen et al. [10] the NNA was only 1.4. Despite this,
it still took five years in five different centers to include
146 patients. That is approximately six patients included
per year per center. This could suggest that definition of
eligibility and/or timing of consent were different than
from our study. The NNA in the study by Katz et al.
[12] was 3.8, mainly because approximately 60% of the
patients declined to participate. In our study also more
than half the patients declined to participate. This is no
different from other placebo-controlled trials on already
established surgical procedures and emphasizes the im-
portance of evaluating the effect from surgical interven-
tions in a similar fashion as for other therapeutic trials
[27], alas prior to introducing a new surgical procedure.
Another reason for the high NNA was that 17 patients
withdrew their initial consent after their MRI. Half of these
patients withdrew consent because, although having a posi-
tive MRI finding, their symptoms had regressed and they
no longer experienced a need for surgery, and the other half
because they would not risk receiving a placebo operation.
Conclusions
In conclusion we have shown that patients are willing to
participate in an orthopedic placebo-controlled surgical
trial. Challenges remain to improve screening proce-
dures for an improved feasibility, and pilot studies are
critical for a realistic assessment of NNS and NNA. We
recommend that when recruiting patients for a placebo-
controlled surgical trial, focus should be on the oral
information given by an orthopedic surgeon and the pa-
tient’s contribution to science should be emphasized.
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